AU2013352369B2 - Novel pharmaceutical composition - Google Patents
Novel pharmaceutical composition Download PDFInfo
- Publication number
- AU2013352369B2 AU2013352369B2 AU2013352369A AU2013352369A AU2013352369B2 AU 2013352369 B2 AU2013352369 B2 AU 2013352369B2 AU 2013352369 A AU2013352369 A AU 2013352369A AU 2013352369 A AU2013352369 A AU 2013352369A AU 2013352369 B2 AU2013352369 B2 AU 2013352369B2
- Authority
- AU
- Australia
- Prior art keywords
- cyclodextrin
- combination
- sulfobutylether
- hypromellose
- hydroxypropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731597P | 2012-11-30 | 2012-11-30 | |
| US61/731,597 | 2012-11-30 | ||
| PCT/US2013/071816 WO2014085371A1 (en) | 2012-11-30 | 2013-11-26 | Novel pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013352369A1 AU2013352369A1 (en) | 2015-05-28 |
| AU2013352369B2 true AU2013352369B2 (en) | 2016-07-28 |
Family
ID=50828398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013352369A Active AU2013352369B2 (en) | 2012-11-30 | 2013-11-26 | Novel pharmaceutical composition |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20150328320A1 (enExample) |
| EP (2) | EP2925299B1 (enExample) |
| JP (1) | JP6232443B2 (enExample) |
| KR (1) | KR102206432B1 (enExample) |
| CN (2) | CN107970214A (enExample) |
| AR (1) | AR093648A1 (enExample) |
| AU (1) | AU2013352369B2 (enExample) |
| BR (1) | BR112015012111A8 (enExample) |
| CA (1) | CA2891346A1 (enExample) |
| CL (1) | CL2015001459A1 (enExample) |
| EA (2) | EA028246B1 (enExample) |
| ES (1) | ES2686730T3 (enExample) |
| IL (3) | IL300664A (enExample) |
| IN (1) | IN2015DN04094A (enExample) |
| MA (1) | MA38121A1 (enExample) |
| MX (1) | MX2015006867A (enExample) |
| MY (1) | MY170427A (enExample) |
| NZ (1) | NZ628395A (enExample) |
| PE (1) | PE20151024A1 (enExample) |
| PH (1) | PH12015501168A1 (enExample) |
| PL (1) | PL2925299T3 (enExample) |
| PT (1) | PT2925299T (enExample) |
| SG (1) | SG11201503688SA (enExample) |
| TN (1) | TN2015000198A1 (enExample) |
| TW (2) | TW201434468A (enExample) |
| UY (1) | UY35157A (enExample) |
| WO (1) | WO2014085371A1 (enExample) |
| ZA (1) | ZA201503346B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102293907B1 (ko) | 2015-06-30 | 2021-08-26 | 한미약품 주식회사 | 이리노테칸 함유 경구용 고형제제 및 그 제조방법 |
| US20200178569A1 (en) * | 2016-04-29 | 2020-06-11 | Alvin Kershman | Method of Coating an Edible Thermoplastic Pet Chew |
| CA3041561A1 (en) | 2016-11-25 | 2018-05-31 | Jiangsu Hengrui Medicine Co., Ltd. | Pyridone derivative pharmaceutical composition and preparation method thereof |
| KR102230721B1 (ko) * | 2019-02-01 | 2021-03-22 | 주식회사 오스코텍 | 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법 |
| WO2021081554A1 (en) * | 2019-10-22 | 2021-04-29 | Chemistryrx | Methods for treating congenital epidermal hyperplasia |
| AU2022414970A1 (en) * | 2021-12-15 | 2024-06-27 | Sillajen, Inc. | Pharmaceutical compositions comprising modified beta-cyclodextrins |
| WO2023219465A1 (ko) * | 2022-05-12 | 2023-11-16 | 주식회사 지뉴브 | 안정한 액상 제약 제제 |
| WO2025132408A2 (en) | 2023-12-21 | 2025-06-26 | Synthon B.V. | Solvates of trametinib |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077871A (en) * | 1997-11-26 | 2000-06-20 | Pfizer Inc. | Droloxifene pharmaceutical compositions |
| US20060014768A1 (en) * | 2004-06-11 | 2006-01-19 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| CA2569850C (en) * | 2004-06-11 | 2011-04-05 | Toshiyuki Sakai | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2,3-d] pyrimidine derivatives and related compounds for the treatment of cancer |
| PL1819353T3 (pl) * | 2004-12-07 | 2011-07-29 | Onyx Therapeutics Inc | Kompozycja do hamowania proteasomu |
| CN1872055A (zh) * | 2005-06-01 | 2006-12-06 | 李�杰 | 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法 |
| ES2364491T5 (es) * | 2005-10-26 | 2015-02-19 | Cydex Pharmaceuticals, Inc. | Composiciones de sulfoalquiléter ciclodextrina y métodos de preparación de las mismas |
| EP2476461A3 (en) * | 2007-01-16 | 2012-10-24 | BiPar Sciences, Inc. | Formulations For Cancer Treatment |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| CN101352419B (zh) * | 2007-07-26 | 2010-08-11 | 天津药物研究院 | 一种醋溴茶碱无糖型颗粒剂及其制备方法 |
| KR101478779B1 (ko) * | 2007-11-22 | 2015-01-05 | 에스케이케미칼주식회사 | 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법 |
| AU2010306653B2 (en) | 2009-10-16 | 2013-10-24 | Novartis Ag | Combination |
| EP2638043B1 (en) | 2010-11-11 | 2017-06-07 | Bayer Intellectual Property GmbH | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| US20130023531A1 (en) | 2011-01-27 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| CA2820709C (en) | 2011-02-28 | 2016-02-16 | Sunshine Lake Pharma Co., Ltd. | Substituted quinoline compounds and methods of use |
| JP5906303B2 (ja) * | 2011-04-07 | 2016-04-20 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | Ａｋｔキナーゼ阻害剤としてのイミダゾピリダジン類 |
| CN102600132B (zh) * | 2012-03-13 | 2014-05-14 | 齐鲁制药有限公司 | 一种含氨磺必利的口服制剂 |
| CN102626394A (zh) * | 2012-03-15 | 2012-08-08 | 合肥科大生物技术有限公司 | 一种精氨酸布洛芬颗粒剂及其制备方法 |
-
2013
- 2013-11-26 EA EA201591047A patent/EA028246B1/ru not_active IP Right Cessation
- 2013-11-26 WO PCT/US2013/071816 patent/WO2014085371A1/en not_active Ceased
- 2013-11-26 EA EA201791411A patent/EA201791411A1/ru unknown
- 2013-11-26 AU AU2013352369A patent/AU2013352369B2/en active Active
- 2013-11-26 IL IL300664A patent/IL300664A/en unknown
- 2013-11-26 MA MA38121A patent/MA38121A1/fr unknown
- 2013-11-26 BR BR112015012111A patent/BR112015012111A8/pt not_active IP Right Cessation
- 2013-11-26 PE PE2015000701A patent/PE20151024A1/es not_active Application Discontinuation
- 2013-11-26 KR KR1020157016931A patent/KR102206432B1/ko active Active
- 2013-11-26 IN IN4094DEN2015 patent/IN2015DN04094A/en unknown
- 2013-11-26 ES ES13857873.7T patent/ES2686730T3/es active Active
- 2013-11-26 IL IL266415A patent/IL266415B2/en unknown
- 2013-11-26 CN CN201711343653.XA patent/CN107970214A/zh active Pending
- 2013-11-26 PT PT13857873T patent/PT2925299T/pt unknown
- 2013-11-26 NZ NZ628395A patent/NZ628395A/en not_active IP Right Cessation
- 2013-11-26 MY MYPI2015001232A patent/MY170427A/en unknown
- 2013-11-26 EP EP13857873.7A patent/EP2925299B1/en not_active Revoked
- 2013-11-26 MX MX2015006867A patent/MX2015006867A/es unknown
- 2013-11-26 JP JP2015545165A patent/JP6232443B2/ja active Active
- 2013-11-26 US US14/647,606 patent/US20150328320A1/en not_active Abandoned
- 2013-11-26 PL PL13857873T patent/PL2925299T3/pl unknown
- 2013-11-26 CN CN201380062796.7A patent/CN104902876B/zh active Active
- 2013-11-26 SG SG11201503688SA patent/SG11201503688SA/en unknown
- 2013-11-26 CA CA2891346A patent/CA2891346A1/en not_active Abandoned
- 2013-11-26 EP EP18173387.4A patent/EP3400933A1/en active Pending
- 2013-11-28 UY UY0001035157A patent/UY35157A/es unknown
- 2013-11-28 AR ARP130104392A patent/AR093648A1/es unknown
- 2013-11-28 TW TW102143365A patent/TW201434468A/zh unknown
- 2013-11-28 TW TW106137040A patent/TW201831187A/zh unknown
-
2015
- 2015-05-13 ZA ZA2015/03346A patent/ZA201503346B/en unknown
- 2015-05-21 IL IL238971A patent/IL238971B/en active IP Right Grant
- 2015-05-22 TN TNP2015000198A patent/TN2015000198A1/fr unknown
- 2015-05-26 PH PH12015501168A patent/PH12015501168A1/en unknown
- 2015-05-29 CL CL2015001459A patent/CL2015001459A1/es unknown
-
2017
- 2017-03-07 US US15/451,888 patent/US20170189408A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077871A (en) * | 1997-11-26 | 2000-06-20 | Pfizer Inc. | Droloxifene pharmaceutical compositions |
| US20060014768A1 (en) * | 2004-06-11 | 2006-01-19 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013352369B2 (en) | Novel pharmaceutical composition | |
| EP4159205B1 (en) | Novel pharmaceutical composition | |
| AU2025242246A1 (en) | Novel pharmaceutical composition | |
| HK1259834A1 (en) | Novel pharmaceutical trametinib composition | |
| HK1209047B (en) | Novel pharmaceutical composition | |
| US20150342957A1 (en) | Combination | |
| US20150306099A1 (en) | Combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: NOVARTIS AG. Free format text: FORMER OWNER(S): GLAXOSMITHKLINE LLC |